Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
A. Fanouriakis, C. Adamichou, S. Koutsoviti, S. Panopoulos +20 more

